Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Breast cancer is the leading cause of cancer-associated death for women worldwide. While chemotherapy is the mainstream treatment for breast cancer, more than 50% of women undergoing chemotherapy will experience at least one chemotherapy-related adverse side effect.
Researchers at Ural Federal University have proposed the use of polyoxometallate nanoclusters as a carrier for chemotherapy drug. It will help to deliver medications precisely to the focus of a pathological process, such as a cancerous tumor, without toxic effects on healthy cells.
Engineered tissues have become a critical component for modeling diseases and testing the efficacy and safety of drugs in a human context.
For patients with cancer, the tumor-killing power of chemotherapeutic drugs is a double-edged sword. While many cancer drugs kill tumor cells, they can also harm healthy cells as they travel throughout the bloodstream.
A study conducted in rats suggests that taking vitamin C may help to counteract the muscle atrophy that is a common side effect of the chemotherapy drug doxorubicin.
Tiny structures called nanoparticles can be used to carry substances to certain parts of the body-;for example, to deliver a chemotherapy drug to a tumor.
Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.
Fundamental science often finds applications beyond its original focus. Previously, scientists found applications for small diameter carbon nanotube porins in energy technology.
Millions of people around the globe are affected by cancer each year; more than 39% of men and women are diagnosed with cancer during their lifetime.
Standard chemotherapies may efficiently kill cancer cells, but they also pose significant risks to healthy cells, resulting in secondary illness and a diminished quality of life for patients. To prevent the previously unavoidable damage, researchers, led by Penn State, have developed a new class of nanomaterials engineered to capture chemotherapy drugs before they interact with healthy tissue.
A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study published in Circulation.
Cancer treatment can be tough on the body, but for the patient to survive the cancer, it's often necessary to go through with the treatment anyway.
Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.
RUDN University and Shahid Beheshti University (SBU) chemist together with colleagues from Iran created a system for targeted delivery of anti-cancer drugs.
Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.
Harmful side effects from a common chemotherapy drug could be the result of a single mutation, according to a study published in Cell Stem Cell.
Aging-US published "The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence" which reported that cellular senescence may be a side effect of chemotherapy and other anti-cancer treatments that may promote inflammation and paracrine secondary senescence in healthy tissues.
Three independent studies in the Journal of Pharmaceutical Analysis explore the potential uses and applications of quantitative analytical tools in the characterization and quality assessment of biological and medicinal compounds.
Unlike conventional cancer drugs that attack and kill cancer cells directly, anti-cancer immunotherapy, which kills cancer cells by strengthening the body's immunity, is a novel type of cancer treatment currently attracting increased attention. Unfortunately, a minority of cancer patients who have some degree of pre-existing immunity only benefit from anti-cancer immunotherapy.
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.